Metrion formed from
management buy out
of Xention, a pioneering
biotech
Metrion was founded in 2015 through a
management buyout of the research division of Xention Limited and its ion channel collaboration programmes
During the period 2002-2005, the Xention team had pioneered the use of automated patch clamp electrophysiology in drug discovery, and subsequently developed substantial expertise in cardiac ion channels, leading to the clinical development of potassium channel inhibitors as novel treatments for atrial fibrillation in collaboration with Servier
management buyout of the research division of Xention Limited and its ion channel collaboration programmes
During the period 2002-2005, the Xention team had pioneered the use of automated patch clamp electrophysiology in drug discovery, and subsequently developed substantial expertise in cardiac ion channels, leading to the clinical development of potassium channel inhibitors as novel treatments for atrial fibrillation in collaboration with Servier
Launch of CiPA compliant
cardiac safety assays
using human iPSCderived
cardiomyocytes
